H1 and Lightship Partner to Accelerate Clinical Studies with Diversity, Equity, and Inclusion Data
Leveraging H1’s Trial Landscape solution, Lightship will incorporate important diversity data into its clinical trials process, bringing life-changing therapies to a more diverse patient population
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) — H1, the connecting force for global HCP, clinical, science, and research information announced today that it is partnering with Lightship, a leading provider of virtual-first and hybrid clinical research solutions, with the aim of making clinical trials more equitable. Healthcare equity cannot be achieved without adequate diversity in clinical trials. Lightship will leverage H1’s Trial Landscape solution to incorporate proprietary demographic and diversity data into its clinical operations and feasibility processes, increasing equity and accelerating clinical trial enrollment and drug development.
“Diverse participation in clinical trials is critical to developing more effective treatments,” says David MacMurchy, CEO, Lightship. “Our partnership with H1 will further enable Lightship to create access for patients and drive equity in clinical research by increasing inclusion of underrepresented people.”
Clinical trial participation does not currently represent the demographic make-up of patients in the US or around the world. A study published in Nature Medicine took an in-depth look at the lack of diversity in clinical trials. The findings show that while African Americans comprise 13.4% of the U.S. population, they accounted for less than 5% of clinical trial patients for 24 cancer drugs approved by the FDA in 2015. And though Hispanics account for 16% of the U.S. population, only 1% are clinical trial participants.
“When we look at clinical trials in the U.S., it’s clear that the patients suffering from a given disease are not being proportionally represented in trials,” said Ariel Katz, founder and CEO, H1. “H1’s integration with platforms like Lightship will accelerate and transform how treatments reach patients – and improve the health of all patients across the globe.”
By combining H1’s Trial Landscape with Lightship’s virtual-first platform and services, we can reduce the burden of participation for patients in clinical research and expand access, choice, and equity.
Learn more about how H1’s Trial Landscape and Lightship are accelerating diverse clinical trials.
About H1
H1 is the connecting force for global HCP, clinical, scientific and research information. The H1 Connect platform democratizes access to HCP knowledge and groundbreaking insights for life sciences, academic medical institutions, health systems, and payors. H1 Connect fuels a robust product suite that helps customers discover and engage industry experts, drive equitable research, access groundbreaking science, and accelerate commercial success with the most robust and accurate healthcare professional data. Learn more at h1.co.
About Lightship
Lightship is leading the way in providing innovative, virtual-first and hybrid clinical research services that create access to clinical trials for all people by removing barriers, scaling inclusion and driving equity in health care. Our flexible delivery model optimizes operational excellence, helmed by colleagues with extensive experience in the clinical research enterprise. Learn more at www.lightship.com
Media contact:
Anya Nelson
Scratch Marketing + Media for H1
anyan@scratchmm.com
M: 617.817.6559
Lightship media contact:
Melissa Daley
Associate Director, Marketing
mdaley@lightship.com
M: 617 645 2415
